Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05412212 · ClinicalTrials.gov registry record · NA
Brief Educational Video for Patients Prescribed LTBI Treatment
A NA study of Latent Tuberculosis, sponsored by Kaiser Permanente.
- Active
- Registry status
- NA
- Development phase
- 1,898
- Enrollment target
- 1
- Study location
NCT05412212 is a NA study of Latent Tuberculosis that is active but no longer recruiting, run by Kaiser Permanente. The registered enrollment target is 1,898 participants, above the 826-participant average among 5 other Latent Tuberculosis trials with a reported enrollment target (130% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05412212, a NA study of Latent Tuberculosis, is active but no longer recruiting, sponsored by Kaiser Permanente.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,898 participants
- Enrollment target
- 1
- Study location
Study Summary
Many patients who are prescribed treatment for latent tuberculosis (LTBI) do not complete treatment. Effective interventions that are low-cost and feasible for large-scale implementation are needed to support efforts to eliminate TB. The investigators hypothesize that a 3-minute educational LTBI video intervention will improve treatment completion compared to standard care (no intervention). A randomized trial will be conducted at Kaiser Permanente Southern California, including adults who are prescribed treatment for LTBI, identified using an electronic health record algorithm. At the time of treatment prescription, patients will be randomized to receive the LTBI video intervention or standard care at a ratio of 2 to 1. Those in the intervention group will be sent a secure text message or e-mail with a link to the video. Individuals who watch the LTBI video will be invited to respond to 4 short questions about their perceptions of the video accessibility and content. The primary outcome is LTBI treatment completion (dispensation of the required number of doses) in the year following prescription order. Secondary outcomes are LTBI treatment initiation (at least one dispensation) in the year following prescription order; initiation and completion within the year following prescription order stratified by LTBI treatment regimen (if feasible); the proportion of individuals randomized to the intervention group who watched the LTBI video; and the perceptions of those who watched the video. The primary analysis will be based on intention-to-treat. Characteristics of individuals in the intervention and standard care groups will be described, and rates of LTBI treatment completion will be calculated. To assess the effect of the intervention, Poisson regression with robust standard errors will be used to estimate unadjusted and adjusted rate ratios and 95% confidence intervals. Per-protocol analyses will also be conducted, comparing those in the intervention group who wat
Conditions Studied
Interventions
- OTHER LTBI video intervention
Study Locations (1)
California
- Kaiser Permanente Southern California Department of Research and Evaluation - Pasadena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,898 participants |
| Start Date | 2022-06-03 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05412212
The ClinicalTrials.gov registry entry for NCT05412212 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 1,898 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 826-participant average among 5 other Latent Tuberculosis trials with a reported enrollment target (130% higher). The listed sponsor is Kaiser Permanente, which has 294 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Latent Tuberculosis appearing as the primary indexed condition, and to 1 intervention - of which LTBI video intervention is the first listed.
NCT05412212 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05412212 about?
NCT05412212 is a clinical study titled "Brief Educational Video for Patients Prescribed LTBI Treatment". Many patients who are prescribed treatment for latent tuberculosis (LTBI) do not complete treatment. Effective interventions that are low-cost and feasible for large-scale implementation are needed to support efforts to eliminate TB. The investigators hypothesize that a 3-minute educational LTBI vid...
What is the current status of trial NCT05412212?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,898 participants. The study started on 2022-06-03. Estimated completion is 2025-12-31.
What conditions does trial NCT05412212 study?
This clinical trial studies the following conditions: Latent Tuberculosis.
What interventions are being tested in trial NCT05412212?
The interventions under investigation include: LTBI video intervention (OTHER).
Who is sponsoring clinical trial NCT05412212?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05412212 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Latent Tuberculosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Economic Incentives and vDOT for Latent Tuberculosis Infection
RECRUITING · NA
-
Training Protocol on the Natural History of Tuberculosis
RECRUITING
-
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
RECRUITING · Phase 2
-
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
ACTIVE NOT RECRUITING · Phase 4
-
Immune Response to Mycobacterium Tuberculosis Infection
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.